Revel Health vs MEDVi
Two single-figure promises, only one of which includes the medication.
Revel Health
Editorial
$149/mo
Two injection lines sold on a single-figure promise: Revel states one price covers consultation, medication, supplies and shipping. Semaglutide is quoted from $199 and tirzepatide from $249. Both also advertise a lower first month, which reduces one bill rather than the rate, and both figures are written as 'From', making them floors. Coverage is stated across 45 states.
Pick it for: Buyers who want the whole service inside one figure
MEDVi
Editorial
$249/mo
One line priced as a price and two priced as a membership. Compounded semaglutide by injection is a flat $249 with no introductory discount shown, while the oral semaglutide and tirzepatide lines publish $99 as a membership fee and state the medication cost separately without naming it. Coverage is stated across 48 states.
Pick it for: Buyers who want MEDVi's injection line specifically
Our verdict
Revel Health states one price covers consultation, medication, supplies and shipping. MEDVi's $99 on two lines is a membership with the drug billed on top and unstated.
What actually separates them
Revel Health and MEDVi state different things about published price and where you can use it. Everything else they publish, they publish the same way.
MEDVi costs $100 more than Revel Health — 67% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,788 at Revel Health against $2,988 at MEDVi — a difference of $1,200.
| Revel Health | MEDVi | |
|---|---|---|
| Published price | $149/mo | $249/mo |
| Where you can use it | 45 states | 48 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.